Can an eye injection boost laser therapy for diabetic retinopathy?
NCT ID NCT07819253
First seen Sep 14, 2026 · Last updated Sep 16, 2026 · Updated 2 times
Summary
Researchers compare two approaches for proliferative diabetic retinopathy, a condition where abnormal blood vessels grow in the retina and can cause vision loss. One group receives standard pan-retinal laser photocoagulation alone. The other receives the same laser treatment plus an injection of ranibizumab, a drug that blocks a vessel-growing protein, into the eye one week before laser. The trial uses optical coherence tomography angiography to measure changes in the density of tiny blood vessels around the macula in 80 participants.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ranibizumab, an anti-VEGF eye injection, combined with pan-retinal laser photocoagulation
- What this could lead to
- If the combination works better, doctors could use ranibizumab injections alongside laser treatment to protect the macula in people with proliferative diabetic retinopathy.
- What could go wrong
- This is a small, single-center study. Adding injections may not improve vessel density more than laser alone, and anti-VEGF eye injections carry small risks of infection, bleeding, or pressure changes in the eye.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
80 people
The number who actually took part.
- Started
-
Jul 2023
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * PDR patients diagnosed clinically and by the presence of neovascularization on optic disc (NVDs) or elsewhere (NVEs) on fluorescein angiography. Exclusion Criteria: * a) History of previous intra ocular surgery, uveitis, glaucoma and significant eye trauma. b) Significant media opacity decreasing image quality (corneal opacity, dense cataract, and vitreous hemorrhage) c) Significant macular edema to overcome errors in segmentation d) Scans with low signal strength index (SSI; \< 50), presence of blink artifacts, and poor fixation leading to motion artifacts. e) History of previous treatment for diabetic retinopathy including intravitreal injection of anti-VEGFs, laser, or vitrectomy f) Presence of vitreo-macular traction
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Proliferative diabetic retinopathy (PDR) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aswan University hospital
Aswān, Aswan Governorate, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.